FindTrial
Sign In

CNTY-101

BIOLOGICAL3 trials

Sponsors

Universitaetsklinikum Erlangen AöR, Century Therapeutics, Inc.

Conditions

Aggressive Non-Hodgkin LymphomaDiffuse Cutaneous Systemic SclerosisIdiopathic Inflammatory MyopathiesIdiopathic inflammatory myositisIndolent Non-Hodgkin LymphomaLupus NephritisR/R CD19-Positive B-Cell MalignanciesSystemic Lupus Erythematosus

Phase 1

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies
TerminatedNCT05336409
Century Therapeutics, Inc.Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, R/R CD19-Positive B-Cell Malignancies
Start: 2023-01-24End: 2025-07-01Updated: 2025-12-18
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
Active, not recruitingNCT06255028
Century Therapeutics, Inc.Diffuse Cutaneous Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Lupus Nephritis +1
Start: 2025-02-06End: 2028-08-31Updated: 2026-01-08
A phase I/II study of CAR-expressing Allogenic iPSC derived NK cells for treatment of autoiMmune disease by B cELl depletion - CARAMEL
RecruitingCTIS2024-519532-16-00
Universitaetsklinikum Erlangen AöRIdiopathic inflammatory myositis, Systemic Lupus Erythematosus, Systemic Sclerosis
Start: 2025-07-30Target: 12Updated: 2026-01-20

Related Papers

Interim results from the ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
Journal of Clinical Oncology2024-06-019 citations
Multiple Doses of Cnty-101, an iPSC-Derived Allogeneic CD19 Targeting CAR-NK Product, Are Safe and Result in Tumor Microenvironment Changes Associated with Response: A Case Study
Blood2023-11-0215 citations
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
Journal of Clinical Oncology2023-06-014 citations